Takeda, Seattle Genetics Report Data for Adcetris in Malignant Lymphoma Compared to Prior Theropy
9 hrs ago | benzinga.com
Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. (NASDAQ: SGEN ) today announced data from a post-hoc analysis examining progression-free survival (PFS) following treatment with ADCETRIS^® (brentuximab vedotin)...
Read more...
Paul Quintaro ADCETRIS ASCT relapsed patient sALCL refractory brentuximab vedotin prior HL therapy PFS Lymphoma